Auauniversity

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/chemo... Instructional Course Director(s) Costas Lallas, MD Thomas Jefferson University Hospital Instructional Course Faculty(s) Anne Calvaresi, DNP, CRNP Thomas Jefferson University Edouard Trabulsi, MD, FACS Sidney Kimmel Medical College at Thomas Jefferson University Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inh